Summary.-Adriamycin (ADR) accumulates in well-perfused organs in the rat. This effect is especially evident for long periods in marrow and spleen of healthy animals. In rats bearing the Brown Norway Acute Myeloid Leukaemia (BNML) the in vivo distribution is significantly different. Maximum ADR levels in those organs which are morphologically infiltrated by leukaemic cells are significantly lower than in normal rats, while the persistence of measurable ADR concentrations does not change. On the contrary, ADR concentrations in organs not infiltrated by leukaemic cells are the same or slightly higher than in normal rats. Possible causes for these differences are either the differential properties of normal and leukaemic cells in their uptake and excretion of ADR, or anatomical and vascular changes. It is evident that, where leukaemia is involved, the relative distribution between serum and tissue is significantly different from normal. This observation may help in the prevention of toxicity by drug monitoring in serum.
THE ANTHRAQUINONE GLYCOSIDE ADRI-AMYCIN (ADR) is of widespread use in the treatment of solid tumours and acute leukaemia (Carter, 1975) . Several studies on the distribution of the drug have revealed its rapid clearance from plasma, selective accumulation in various organs and slow elimination via urinary and biliary pathways in the rat, monkey and man (Chan et al., 1978; Wilkinson et al., 1979) . Little information is available on the comparative distribution kinetics of ADR between normal tissues and malignant tumours in vivo. In mice and rats bearing solid tumours, it has been observed that ADR concentrations in metastases were higher than those in the parent tumours , while the drug penetrates less extensively into solid tumours than into most normal tissues (DiFronzo et al., 1973) . However, in acute leukaemia, a widely disseminated malignant disease, tumour cells are present in many organs in varying numbers. The differential drug
Requests for reprints to P. Soinnev-el(l. uptake (Sonneveld & Van den Engh, 1981.) and sensitivity (Buick et al., 1979; between leukaemic and normal cells observed in vitro may thus very well influence the amount of drug taken up in vivo by an organ, especially if it is infiltrated by a large number of leukaemic cells. In view of the clinically observed variations in drug response among acute-leukaemia patients, the different drug uptake of normal and malignant cells, as well as the number of leukaemic cells, may be relevant factors in the in vivo distribution of ADR. The present study was initiated to investigate whether the distribution kinetics of ADR differ between normal and leukaemia-bearing rats using an experimental leukaemia model which has been proved to resemble closely acute myeloid leukaemia in man, and is highly sensitive to the antitumour activity of ADR. (Hagenbeek, 1977) and can be summarized as follows:
(1) the net growth rate is slow; (2) (Schwartz, 1973 Table I . Serum (Fig. l) Hagenbeek, 1977.) tion a rapid initial decrease of the serum concentration of ADR can be seen in both normal and leukaemic rats followed by a long excretory phase. These concentration-time curves suggest extensive accumulation of the drug in the tissues. The values for leukaemic animals are consistently higher than those for normal rats. The observed differences are significant for a number of points.
Spleen (Fig. 2) . ADR levels in the spleen reach values 1O x the serum concentration within 10 min of drug administration. Despite the initial decrease in the first 30 min, the spleen drug levels remain high for 24 h in normal rats. In leukaemic animals, in which the spleen weight has increased 5-fold and large numbers of leukaemic cells have infiltrated the organ, the drug levels are generally lower by a factor 1-5-2 (in the first 24 h) than those of normal rats. Marrow (Fig. 3 ).-Considerable concentrations of ADR are found in the femoral bone marrow of both normal and leukaemic rats. In Fig. 3 The concentration-time curve of ADR in marrow is characterized by a gradual increase both in normal and leukaemic rats. However, in BNML rats the large presence of leukaemic cells apparently inhibits drug accumulation. In BN and BNML animals the observed peak concentrations in marrow are considerably higher than in the other organs investigated in this study.
Other organs.- Table II shows the disappearance of ADR in several organs which, as judged by microscopy, are hardly if at all infiltrated by leukaemic cells, such as lungs, heart, kidneys and liver. Except in liver, no significant differences can be seen between the concentration-time relationships in organs from normal and leukaemic organs. The disappearance of ADR from the liver seems to be slower in leukaemic than in normal rats.
Renal elimination
To determine the renal elimination of ADR, rats were caged in metabolic cages, in which urine is collected without the chance of pollution by faeces (Hagenbeek, 1977) . Fig. 4 shows the cumulative renal elimination of ADR over 72 h in normal animals. The mean volume of urine in which this amount of ADR was excreted was 21 ml. The renal function as measured by the creatinine content of the serum changed significantly during progress of the disease, and was actually higher by a factor of 1-4 at Day 15 after inoculation of the leukaemia, than in healthy controls.
Biliary excretion
To determine the excretion of ADR in bile, 9 animals were anaesthetized with ketamine HCL and a teflon drain with a diameter of 1 mm was inserted into the w/ ,/ / biliary duct. The drain was led through the cutis and inserted into a 5ml tube.
Saline (O*9%0) was administered i.v. at a rate of 2 ml/h by an infusion pump during sampling in order to maintain the fluid balance. After the end of the anaesthesia, ADR was administered i.v. in a single dose and the bile was collected at regular intervals. In Fig. 5 , the cumulative biliary elimination is plotted for 24 h. A rapid initial excretion can be observed for 6 h, after which the elimination diminishes. These observations are from healthy rats only, since leukaemic rats did not survive the surgery.
Metabolism
Using the described TLC chromatographic procedure in the first 24 165 g, and that the serum volume amounts to 5*7 ml, the conclusion is that ADR is redistributed very rapidly to the tissues. Calculated per g of tissue, a great part of the administered dose accumulates in the marrow cells of both BNML and normal rats. In view of the severe toxicity of ADR to the normal haemopoietic system, which is located in the marrow, this toxicity is not only due to the haemopoietic system being composed of rapidly dividing cells, but the high concentration over a prolonged period may also be responsible. In leukaemic animals, the marrow concentration is considerably lower. Leukaemic cells, which contribute greatly to the population of the femoral marrow, probably take up ADR less than do normal haemopoietic cells. A similar phenomenon can be observed in the spleen; during the 24h observation period, the concentration per g of spleen tissue is relatively constant in both normal and 15-day leukaemic rats. However, the concentration in leukaemic spleen is significantly lower, but shows the same disappearance pattern as the normal intracellular spleen concentration of normal spleen cells. In view of the increase in the spleen weight from 0*35 g to 1-28 g at Day 15, reduced availability of ADR to the individual cells in the spleen as a result of pathological deviations of the vascular structure should be considered as a possible causative factor. This reduction resembles that seen in marrow infiltrated with large numbers of leukaemic cells. Although the total ADR in a leukaemic spleen is greater than in the normal spleen, the concentration per cell is lower.
At the same time, an increase in serum concentration can be seen during the first 8 h. A redistribution of ADR presumably occurs when a certain number of tumour cells is present in the body. In that case, it is impossible to estimate the concentration of ADR in the spleen from the serum curve, since there is no information on the exact relationship between these two organs.
The liver, which increases in weight by a factor of 1*72, shows only moderate deviations from the original concentrationtime curve. Other organs such as the lungs, the heart and the kidneys show the same disappearance curve in normal and leukaemic animals. On histological examination, no leukaemic infiltration into these organs can be demonstrated and no increase in weight is observed (Hagenbeek, 1977) . The quantitative differences between the serum curves of BN and BNML rats can be attributed to the lower drug levels in leukaemia-infiltrated organs: spleen and marrow.
Previously, Donelli (1976) had found reduced levels of ADR in tumour-infiltrated mouse lungs, when compared with normal lungs. In these animals, the excretion of ADR occurs according to the pathways which have been described (Bachur, 1975; Benjamin et al., 1973 Benjamin et al., , 1974 . Since the contribution of an enterohepatic recirculation is not defined, it is uncertain how far the results can be compared. An 8% biliary elimination in 24 h, compared with a 50%o excretion in the faeces in 7 days, does not provide strong evidence for the relevance of such an enterohepatic circulation. The urinary route is the major pathway of excretion in the normal rat (26% in 72 h). However, the decrease of normal renal elimination function, as measured by the creatinine content of peripheral blood, causes a decreased excretion of ADR in leukaemic rats. This decrease in excretory function leads to prolonged elevated levels of ADR in all normal tissues of leukaemic rats. A great proportion of the effective tumourreducing function and the toxicity to normal tissues is probably a direct result of this phenomenon, especially since ADR elimination from many organs is slow.
Our results indicate significant differences in the general distribution of ADR between normal and leukaemic animals. These differences cannot be quantitated merely from the serum cutrve. In both normal and leukaemic animals, various organs show selective accumulation of the drug. It can be concluded, therefore, that an estimation of the drug level at the tumour site cannot be made without information on the tumour load and the normal drug distribution.
